Publication:
Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population.

dc.contributor.authorLópez-Cortés, Luis F
dc.contributor.authorViciana, Pompeyo
dc.contributor.authorGirón-González, José A
dc.contributor.authorRomero-Palacios, Alberto
dc.contributor.authorMárquez-Solero, Manuel
dc.contributor.authorMartinez-Perez, Maria A
dc.contributor.authorLópez-Ruz, Miguel A
dc.contributor.authorTorre-Lima, Javier de la
dc.contributor.authorTéllez-Pérez, Francisco
dc.contributor.authorDelgado-Fernández, Marcial
dc.contributor.authorGarcia-Lázaro, Milagros
dc.contributor.authorLozano, Fernando
dc.contributor.authorMohamed-Balghata, Mohamed O
dc.contributor.authoraffiliation[López-Cortés,LF; Viciana,P] Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain. [Girón-González,JA] Hospital Universitario Puerta del Mar, Cádiz, Spain. [Romero-Palacios,A] Hospital Universitario de Puerto Real, Cádiz, Spain. [Márquez-Solero,M] Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Martinez-Perez,MA] Hospital Universitario San Cecilio, Granada, Spain. [López-Ruz,MA] Hospital Universitario Virgen de las Nieves, Granada, Spain. [Torre-Lima,J de la] Hospital Costa del Sol, Málaga, Spain. [Téllez-Pérez,F] Hospital La Línea, Cádiz, Spain. [Delgado-Fernández,M] Hospital Universitario Carlos Haya, Málaga, Spain. [Garcia-Lázaro,M] Hospital Universitario Reina Sofía, Córdoba, Spain. [Lozano,F] Hospital Universitario de Valme, Sevilla, Spain. [Mohamed-Balghata,MO] Complejo Hospitalario de Jaén, Jaén, Spain. [López-Cortés,LF] Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocío, Sevilla, Spain.es
dc.date.accessioned2014-06-09T12:39:44Z
dc.date.available2014-06-09T12:39:44Z
dc.date.issued2014-05-16
dc.descriptionJournal Article; ClinicalTrials.gov NCT01437241.es
dc.description.abstractEtravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase inhibitors (NRTIs). This multicenter study aimed to assess the efficacy of this combination in two scenarios: group A) subjects without virologic failure on or no experience with non-nucleoside reverse-transcriptase inhibitors (NNRTIs) switched due to adverse events and group B) subjects switched after a virologic failure on an efavirenz- or nevirapine-based regimen. The primary endpoint was efficacy at 52 weeks analysed by intention-to-treat. Virologic failure was defined as the inability to suppress plasma HIV-RNA to <50 copies/mL after 24 weeks on treatment, or a confirmed viral load >200 copies/mL in patients who had previously achieved a viral suppression or had an undetectable viral load at inclusion. Two hundred eighty seven patients were included. Treatment efficacy rates in group A and B were 88.0% (CI95, 83.9-92.1%) and 77.4% (CI95, 65.0-89.7%), respectively; the rates reached 97.2% (CI95, 95.1-99.3%) and 90.5% (CI95, 81.7-99.3), by on-treatment analysis. The once-a-day ETV treatment was as effective as the twice daily dosing regimen. Grade 1-2 adverse events were observed motivating a treatment switch in 4.2% of the subjects. In conclusion, ETV (once- or twice daily) plus two analogs is a suitable, well-tolerated combination both as a switching strategy and after failure with first generation NNRTIs, ensuring full drug activity. es
dc.description.versionYeses
dc.identifier.citationLópez-Cortés LF, Viciana P, Girón-González JA, Romero-Palacios A, Márquez-Solero M, Martinez-Perez MA, et al. Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population. PLoS ONE. 2014; 9(5):e97262es
dc.identifier.doi10.1371/journal.pone.0097262
dc.identifier.essn1932-6203
dc.identifier.pmcPMC4023987
dc.identifier.pmid24836963
dc.identifier.urihttp://hdl.handle.net/10668/1629
dc.journal.titlePloS One
dc.language.isoen
dc.organizationAGS Campo de Gibraltar Oeste
dc.organizationAGS Sur de Sevilla
dc.provenanceRealizada la curación de contenido 26/06/2025
dc.publisherPublic Library of Sciencees
dc.relation.publisherversionhttp://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0097262es
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject Reverse Transcriptase Inhibitors es
dc.subject Nevirapine es
dc.subject Protease Inhibitors es
dc.subject Viral Load es
dc.subject Intention to Treat Analysis es
dc.subject Antiviral Agents es
dc.subject Treatment Outcome es
dc.subject HIV Infectionses
dc.subjectAGS Campo de Gibraltar Oeste
dc.subjectAGS Sur de Sevilla
dc.subject.decsEtravirina
dc.subject.decsPiridazinas
dc.subject.decsInhibidores de Proteasas
dc.subject.decsSeropositividad para VIH
dc.subject.decsFármacos Anti-VIH
dc.subject.decsInhibidores de la Proteasa VIH
dc.subject.decsInhibidores de Transcriptasa Inversa
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyridazineses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitorses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Multicenter Studies as Topices
dc.subject.meshMedical Subject Headings::Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections::HIV Seropositivityes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Anti-HIV Agentses
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors::HIV Protease Inhibitorses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Nucleic Acid Synthesis Inhibitors::Reverse Transcriptase Inhibitorses
dc.titleClinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population.es
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Lopez-Cortes_ClinicalAndVirological.pdf
Size:
1007.99 KB
Format:
Adobe Portable Document Format
Description: